Open AccessInactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age‐Dependent Manner
Author(s) -
Glendie Marcelin,
Hilliary M. Bland,
Nicholas J. Negovetich,
Matthew R. Sandbulte,
Ali H. Ellebedy,
Ashley Webb,
Yolanda Griffin,
Jennifer DeBeauchamp,
Janet E. McElhaney,
Richard J. Webby
Publication year - 2010
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/657084
Subject(s) - pandemic , neuraminidase , vaccination , virology , virus , antibody , hemagglutinin (influenza) , human mortality from h5n1 , influenza a virus , immunology , medicine , live attenuated influenza vaccine , h5n1 genetic structure , immunity , biology , disease , influenza vaccine , immune system , covid-19 , infectious disease (medical specialty)
Levels of preexisting antibodies to the hemagglutinin of pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1) virus positively correlate with age. The impact of contemporary seasonal influenza vaccines on establishing immunity to other pandemic H1N1 proteins is unknown. We measured serum antibodies to the neuraminidase (NA) of pandemic H1N1 in adults prior to and after vaccination with seasonal trivalent inactivated influenza vaccines. Serum antibodies to pandemic H1N1 NA were observed in all age groups; however, vaccination elevated levels of pandemic H1N1 NA antibodies predominately in elderly individuals (age, ⩾60 years). Therefore, contemporary seasonal vaccines likely contribute to reduction of pandemic H1N1-associated disease in older individuals.